Psychedelic Drugs

Global Psychedelic Drugs Market to Reach US$3.8 Billion by 2030

The global market for Psychedelic Drugs estimated at US$1.9 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 11.6% over the analysis period 2024-2030. Gamma Hydroxybutyric Acid, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Ketamine segment is estimated at 9.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$530.0 Million While China is Forecast to Grow at 16.0% CAGR

The Psychedelic Drugs market in the U.S. is estimated at US$530.0 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$797.5 Million by the year 2030 trailing a CAGR of 16.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 10.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR.

Global Psychedelic Drugs Market – Key Trends & Drivers Summarized

Why Are Psychedelic Drugs Gaining Mainstream Acceptance in Medicine?

The global psychedelic drugs market has witnessed a remarkable resurgence, driven by increasing scientific validation of their therapeutic benefits in treating mental health disorders such as depression, anxiety, PTSD, and addiction. Historically associated with countercultural movements and recreational use, psychedelics such as psilocybin, LSD, MDMA, DMT, and ketamine are now being rigorously studied for their potential in psychiatric care. The growing mental health crisis, characterized by rising cases of treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), has created an urgent need for novel treatment modalities beyond conventional antidepressants. Clinical trials and research studies have demonstrated that psychedelics, when used under controlled conditions, can induce profound neuroplasticity, promoting long-term psychological healing in a way that traditional pharmaceuticals often fail to achieve. The shift in regulatory stances, with the FDA granting "breakthrough therapy" designations to psilocybin and MDMA-based treatments, has further accelerated interest in this field. As major pharmaceutical companies and biotech startups enter the space, the psychedelic drugs market is moving toward a more structured, clinically validated, and widely accepted therapeutic model, bringing these substances from the fringes into mainstream medical applications.

How Is Research and Regulatory Evolution Fueling Market Expansion?

Regulatory developments and scientific advancements are playing a crucial role in the commercialization of psychedelic drugs. The FDA’s recognition of the potential therapeutic benefits of psychedelics has led to expedited pathways for drug approval, enabling companies to fast-track research and development efforts. In parallel, countries such as Canada, Australia, and parts of Europe have begun exploring policy changes to accommodate medical use, while several U.S. states have decriminalized or legalized psychedelics for therapeutic applications. The growing body of clinical evidence supporting the efficacy of psychedelic-assisted therapy has attracted significant investment, with venture capital firms, pharmaceutical giants, and mental health organizations funding research into psilocybin-based antidepressants, MDMA-assisted psychotherapy, and ketamine infusions. Research institutions and biotech firms are focusing on optimizing psychedelic formulations, improving delivery mechanisms, and enhancing safety profiles to ensure that these compounds can be integrated into conventional medical frameworks. Furthermore, the expansion of digital therapeutics and AI-driven mental health platforms is expected to complement psychedelic therapy, offering guided treatment experiences and post-session support. The shift toward evidence-based treatment protocols and physician-led administration models is helping psychedelic drugs gain legitimacy as serious contenders in the mental health treatment landscape.

How Are Commercialization Strategies and Investment Trends Reshaping the Industry?

The commercialization of psychedelic drugs is gaining momentum as pharmaceutical companies and mental health clinics develop structured frameworks for widespread adoption. One of the biggest shifts in the industry is the establishment of psychedelic-assisted therapy clinics, where patients undergo controlled therapeutic sessions under medical supervision. The increasing number of startups specializing in psychedelic research has led to the development of novel formulations, microdosing strategies, and extended-release versions of these compounds to enhance their therapeutic potential. Companies are also exploring synthetic derivatives of naturally occurring psychedelics, aiming to minimize side effects while maximizing clinical efficacy. The rapid growth of the market has drawn significant investor interest, with several psychedelic biotech firms going public and raising capital to fund large-scale clinical trials. Moreover, collaborations between academic institutions, mental health organizations, and pharmaceutical companies are accelerating the pipeline for FDA and EMA approvals, bringing psychedelic therapies closer to market availability. As the demand for alternative mental health treatments grows, traditional pharmaceutical players are also entering the space, either through acquisitions or strategic partnerships, further driving the sector’s expansion. With a projected increase in mental health spending worldwide, the business model for psychedelic drug therapy is expected to evolve, incorporating insurance reimbursement models and government-backed mental health initiatives.

What Are the Key Growth Drivers of the Psychedelic Drugs Market?

The growth in the global psychedelic drugs market is driven by several factors, including increasing prevalence of mental health disorders, rising acceptance of alternative therapies, and regulatory shifts favoring psychedelic-assisted treatment. The significant limitations of conventional antidepressants and the growing cases of treatment-resistant depression have intensified the demand for novel therapeutic options, positioning psychedelics as a viable alternative. Advances in neuroscience and psychopharmacology have provided a better understanding of how psychedelics impact brain function, fostering greater confidence among healthcare professionals and researchers. The increasing destigmatization of psychedelics, coupled with advocacy from mental health organizations and influencers, has also played a role in market expansion. The growing number of clinical trials evaluating psilocybin, MDMA, and ketamine for mental health applications has contributed to greater institutional investment in the field. The rise of psychedelic wellness retreats, digital integration of mental health support, and expansion of therapy clinics specializing in psychedelic-assisted treatments are further broadening the market’s reach. Additionally, as pharmaceutical regulations evolve to accommodate psychedelic medicine, large-scale production and commercialization efforts are expected to accelerate. The integration of personalized treatment protocols, AI-driven patient monitoring, and telemedicine support systems will likely enhance the accessibility and effectiveness of psychedelic therapy, ensuring long-term market growth.

SCOPE OF STUDY:

The report analyzes the Psychedelic Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Type (Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels); Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Atai Life Sciences
• Beckley Psytech
• Bexson Biomedical
• Biomind Labs
• Bright Minds Biosciences
• CaaMTech
• Compass Pathways
• Cybin
• Delix Therapeutics
• Eleusis
• Entheon Biomedical
• Enveric Biosciences
• Field Trip Health
• GH Research
• Gilgamesh Pharmaceuticals
• Havn Life Sciences
• Jazz Pharmaceuticals
• Johnson & Johnson
• Lykos Therapeutics
• Mind Medicine (MindMed)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.